Literature DB >> 2036991

Estrogen-like activity of a subpopulation of natural antiestrogen receptor autoantibodies in man.

A Borkowski1, M Gyling, C Muquardt, J J Body, G Leclercq.   

Abstract

We recently reported that a subpopulation of immunoglobulin G (IgG) in man interacts with the hormone-binding site of estrogen receptors (ER), competes with [3H]estradiol (E2) uptake, and decreases effective ER concentrations in cell cultures. The present work further characterizes the immunological properties of these antibodies and defines their biological activity. Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting techniques, enriched preparations of the natural anti-ER IgG subpopulation (IgGs) were found to specifically immunoprecipitate ER extracted from MCF-7 mammary carcinoma cells and to compete with [3H]tamoxifen-aziridine for ER binding. During 18-h incubations IgGs decreased [3H]E2 binding capacity of MCF-7 cells in a dose-dependent manner similar to E2. Like E2 but unlike antiestrogens, this biological effect corresponded to down-regulation of the receptor protein and depended on a mechanism specifically inhibited by actinomycin D. Moreover, IgGs antagonized the decrease of [3H]E2 binding capacity produced by the strong antiestrogen methyl-hydroxytamoxifen; this antagonism was additive to that of E2. On the other hand, IgGs like estrogens increased progesterone receptor concentrations and cathepsin D secretion. The biological activity of IgGs was neutralized by anti-IgG antibodies and by ICI 164,384, a "pure" steroid antagonist of E2, confirming that immunoglobulins G were responsible for this activity and acted at the E2-binding site. These observations indicate that some natural antibodies in man can function like potent estrogens on ER and mammary cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2036991     DOI: 10.1210/endo-128-6-3283

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Ratio of Circulating Estrogen Receptors Beta and Alpha (ERβ/ERα) Indicates Endoscopic Activity in Patients with Crohn's Disease.

Authors:  Pablo M Linares; Alicia Algaba; Ana Urzainqui; Mercedes Guijarro-Rojas; Rafael González-Tajuelo; Jesús Garrido; María Chaparro; Javier P Gisbert; Fernando Bermejo; Iván Guerra; Víctor Castellano; María-Encarnación Fernández-Contreras
Journal:  Dig Dis Sci       Date:  2017-08-19       Impact factor: 3.199

2.  Human breast tumors containing non-DNA-binding immunoreactive (67 kDa) estrogen receptor.

Authors:  P A Montgomery; G K Scott; M C Luce; M Kaufmann; C C Benz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  Tumour cell binding by a human monoclonal IgM antibody from the spleen of a non-tumour-associated patient is due to somatic mutations in the VH gene.

Authors:  J Bohn; B Niemann; D Roggenbuck; W Döcke; S Jahn
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

4.  Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their levels correlate with breast cancer cell proliferation.

Authors:  Angela Maselli; Sara Capoccia; Patrizia Pugliese; Carla Raggi; Francesca Cirulli; Alessandra Fabi; Walter Malorni; Marina Pierdominici; Elena Ortona
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

Review 5.  Immunomodulation of carcinogens-induced steroids-dependent human diseases.

Authors:  Andrew N Glushkov; Elena G Polenok
Journal:  Saudi J Biol Sci       Date:  2017-10-03       Impact factor: 4.219

Review 6.  Natural Anti-Estrogen Receptor Alpha Antibodies Able to Induce Estrogenic Responses in Breast Cancer Cells: Hypotheses Concerning Their Mechanisms of Action and Emergence.

Authors:  Guy Leclercq
Journal:  Int J Mol Sci       Date:  2018-01-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.